Почетна › Колоректален карцином › Канзас

Клинички испитувања за Колоректален карцином во Канзас

19 студии за Колоректален карцином бараат учесници на локации во Канзас.

Градови во Канзас

Официјален текст на студијата (англиски)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Central Care Cancer Center - Garden City, Garden City
Central Care Cancer Center - Great Bend, Great Bend
Veteran Administration Eastern Kansas Healthcare, Leavenworth
и уште 4

Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери

Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069

Family Communications After Genetic Testing

Central Care Cancer Center - Garden City, Garden City
Central Care Cancer Center - Great Bend, Great Bend
Mercy Hospital Pittsburg, Pittsburg
и уште 1

Се регрутираДобредојдени се здрави волонтери

Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT07143487

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Westwood Cancer Center, Westwood

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT05803382

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Westwood

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06218914

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Cancer Center of Kansas, Wichita

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06750094

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Cancer Center of Kansas, Wichita

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06662786

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

University of Kansas, Fairway

Се регрутираФаза 1

Возраст од 12 до 120 · Сите полови · Ажурирано 23.9.2026 · NCT04222413

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The University of Kansas Clinical Research Center, Westwood

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06445062

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Indian Creek Campus, Overland Park
и уште 1

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT06696768

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Clinical Study Site, Westwood

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT07228832

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

The University of Kansas Cancer Center, Kansas City

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 11.8.2026 · NCT05592626

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Cancer Center-Overland Park, Overland Park
и уште 2

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 31.7.2026 · NCT05691491

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

Cancer Centers of Kansas, Wichita

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 15.7.2026 · NCT06937177

Lead-212 PSV359 Therapy for Patients With Solid Tumors

University of Kansas, Kansas City

Се регрутираФаза 1/2

Возраст од 18 до 90 · Сите полови · Ажурирано 6.7.2026 · NCT06710756

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

The University of Kansas Clinical Research Center, Fairway

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 1.6.2026 · NCT06607458

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

Central Care Cancer Center - Garden City, Garden City
Central Care Cancer Center - Great Bend, Great Bend
Mercy Hospital Pittsburg, Pittsburg

Се регрутираФаза 3Добредојдени се здрави волонтери

Возраст 18 и постари · Сите полови · Ажурирано 31.3.2026 · NCT07018869

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

The University of Kansas Cancer Center, Fairway

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 18.3.2026 · NCT06244771

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

HaysMed, Hays
Lawrence Memorial Hospital, Lawrence
The University of Kansas Cancer Center - Olathe, Olathe
и уште 6

Се регрутираНабљудувачка студија

Возраст 18 и постари · Сите полови · Ажурирано 17.3.2026 · NCT06418204

A Study of IBI363 in Subjects with Advanced Solid Malignancies

University of Kansas Medical Center (KUMC), Fairway

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 19.12.2024 · NCT06281678

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.